Browsing by Author "Direskeneli, Haner"
Now showing 1 - 18 of 18
- Results Per Page
- Sort Options
Publication A nationwide experience with the off label use of interleukin 1 targeting treatment in familial mediterranean fever patients(Wiley, 2016-10-01) Akar, Servet; Çetin, Pınar; Kalyoncu, Umut; Karadağ, Ömer; Sarı, İsmail; Çınar, Muhammed; Yılmaz, Sedat; Onat, Ahmet Mesut; Kısacık, Bünyamin; Erden, Abdülsamet; Balkarlı, Ayşe; Küçükşahin, Orhan; Öner, Sibel Yılmaz; Şenel, Soner; Tufan, Abdurrahman; Direskeneli, Haner; Öksüz, Mustafa Ferhat; Pehlivan, Yavuz; Bayndır, Özün; Keser, Gökhan; Aksu, Kenan; Omma, Ahmet; Kaşifoğlu, Timuçin; Ünal, Ali Uğur; Yıldız, Fatih; Balcı, Mehmet Ali; Yavuz, Şule; Erten, Şükran; Özgen, Metin; Sayarıoğlu, Mehmet; Doğru, Atalay; Çetin, Gözde Yıldırım; Alibaz-Öner, Fatma; Tezcan, Mehmet Engin; Pamuk, Ömer Nuri; Önen, Fatos; Öksüz, Mustafa Ferhat; PEHLİVAN, YAVUZ; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; JXF-7598-2024; AAG-8227-2021Item Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis(Springer, 2007) İnanç, Murat; Direskeneli, Haner; Kamalı, Sevil; Kasapoğlu, Günal Esen; Elbir, Yeşim; Dalkılıç, Ediz; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Ramotoloji Bilim Dalı.; 6506739457Our aim is to assess the prevalence and associated clinical features of anti-CCP (cyclic citrullinated peptide) antibodies for RF (rheumatoid factor)-positive and RF-negative rheumatoid arthritis (RA) and psoriatic arthritis (PsA). In a prospective, cross-sectional, multi-centre study, we determined the titres of anti-CCP antibodies in 208 RA patients (129 RF-positive, 79 RF-negative), 56 PsA patients and 39 healthy controls (HC). Clinical parameters including disease activity (disease activity score 28-DAS28), physical disability (health assessment questionnaire-HAQ), functional capacity (functional class) and radiological erosions were investigated in patients with RA. In PsA patients, clinical and radiological features were determined. Anti-CCP2 antibodies were measured using a second-generation anti-CCP enzyme-linked immunosorbent assay (Euro-Diagnostica, Netherlands). One-hundred four of 129 RF-positive RA (81%), 16 of 79 RF-negative RA (20%), seven of 56 PsA patients (12.5%) and none of the HC had anti-CCP antibodies. RA patients with anti-CCP antibodies had significantly higher disease activity, greater loss of function and more frequent erosive disease than anti-CCP antibody-negative group. In subgroup analysis, anti-CCP antibodies in RF-negative patients were also associated with erosive disease. All PsA patients with anti-CCP antibodies had symmetric arthritis with higher number of swollen joints. The prevalence of anti-CCP antibodies in RF-positive RA patients was significantly higher than in RF-negative RA and PsA patients. Anti-CCP antibodies were also associated with erosive disease in RF-negative RA patients. Both anti-CCP and RF tests were negative in 30% of the patients. Anti-CCP positivity was a frequent finding in PsA and associated with symmetrical polyarthritis.Item Assessment of damage and prognosis in patients with adult iga vasculitis: Retrospective multicentered cohort study(Bmj Publishing Group, 2017-06) Alibaz, Öner; Omma, Ahmet; Sarı, Alper; Karadağ, Ömer; Cansu, Döndü Üsküdar; Beş, Cemal; Yıldız, Fatih; Yılmaz, Sema; Balkarlı, Ayşe; Üreyen, S.; Direskeneli, Haner; Öksüz, Mustafa Ferhat; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.Item Assessment of severity and risk factors of post-thrombotic syndrome in vascular behcet disease: Muticentered retrospective study(Wiley, 2018-09) Aksoy, Aysun; Çolak, Seda; Omma, Ahmet; Ergelen, Rabia; Direskeneli, Haner; Alibaz, Fatma Öner; Yağız, Burcu; Coşkun, Belkıs Nihan; Bolca, Naile; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Radyoloji Anabilim Dalı.; 0000-0003-0298-4157; AAG-7155-2021Item Behçet disease with vascular involvement: Effects of different therapeutic regimens on the incidence of new relapses(Lippincott Williams & Wilkins, 2015-02) Öner, Fatma Alibaz; Karadeniz, Aslı; Yılmaz, Sema; Balkarlı, Ayşe; Kimyon, Gezmiş; Yazıcı, Ayten; Çınar, Muhammet; Yılmaz, Sedat; Yıldız, Fatih; Bilge, Şule Yaşar; Bilgin, Emre; Omma, Ahmet; Çetin, Gözde Yıldırım; Çağatay, Yonca; Karaaslan, Yaşar; Sayarlıoğlu, Mehmet; Kalyoncu, Umut; Karadağ, Ömer; Kaşifoğlu, Timuçin; Erken, Eren; Pay, Salih; Çefle, Ayşe; Kısacık, Bünyamin; Onat, Ahmet Mesut; Çobankara, Veli; Direskeneli, Haner; Coşkun, Belkıs Nihan; Pehlivan, Yavuz; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; 0000-0003-0298-4157; AAG-7155-2021; AAG-8227-2021; 55646165400; 13205593600Vascular involvement is one of the major causes of mortality and morbidity in Behcet disease (BD). There are no controlled studies for the management of vascular BD (VBD), and according to the EULAR recommendations, only immunosuppressive (IS) agents are recommended. In this study, we aimed to investigate the therapeutic approaches chosen by Turkish physicians during the initial event and relapses of VBD and the association of different treatment options with the relapses retrospectively. Patients with BD (n = 936, female/male: 347/589, mean age: 37.6 +/- 10.8) classified according to ISG criteria from 15 rheumatology centers in Turkey were included. The demographic data, clinical characteristics of the first vascular event and relapses, treatment protocols, and data about complications were acquired. VBD was observed in 27.7% (n = 260) of the patients during follow-up. In 57.3% of the VBD patients, vascular involvement was the presenting sign of the disease. After the first vascular event, ISs were given to 88.8% and AC treatment to 59.8% of the patients. Median duration of AC treatment was 13 months (1-204) and ISs, 22 months (1-204). Minor hemorrhage related to AC treatment was observed in 7 (4.7%) patients. Asecond vascular event developed in 32.9% (n = 86) of the patients. The vascular relapse rate was similar between patients taking only ISs and AC plus IS treatments after the first vascular event (29.1% vs 22.4%, P = 0.28) and was significantly higher in group taking only ACs than taking only ISs (91.6% vs 29.1%, P < 0.001). During follow-up, a third vascular event developed in 17 (n = 6.5%) patients. The relapse rate was also similar between the patients taking only ISs and AC plus IS treatments after second vascular event (25.3% vs 20.8%, P = 0.93). When multivariate analysis was performed, development of vascular relapse negatively correlated with only IS treatments. We did not find any additional positive effect of AC treatment used in combination with ISs in the course of vascular involvement in patients with BD. Severe complications related to AC treatment were also not detected. Our results suggest that short duration of IS treatments and compliance issues of treatment are the major problems in VBD associated with vascular relapses during follow-up.Publication Clinical features of takayasu's arteritis from an inception cohort: Early disease is characterized by 'systemic inflammation'(Wiley, 2016-10-01) Alibaz-Öner, Fatma; Ünal, Ali Uğur; Onat, Ahmet Mesut; Kısacık, Bünyamin; Zengin, Orhan; Karadağ, Ömer; Erden, Abdulsamet; Yarkan, Handan; Akar, Servet; Yıldız, Fatih; Erken, Eren; Özer, Hüseyin; Omma, Ahmet; Özbalkan, Zeynep; Karaaslan, Yaşar; Bes, Cemal; Öner, Sibel Yılmaz; Kanıtez, Nilüfer Alpay; Bayndır, Özün; Yavuz, Şule; Düzgün, Nursen; Tufan, Ayşe Nur; Dalkılıç, Ediz; Yoshifuji, Hajime; Tufan, Abdurrahman; Akyol, Lütfi; Öztürk, Mehmet Akif; Sayarlıoğlu, Mehmet; Aksu, Kenan; Keser, Gökhan; Kiraz, Sedat; Pamuk, Ömer Nuri; Önen, Fatoş; Direskeneli, Haner; Tufan, Ayse Nur; DALKILIÇ, HÜSEYİN EDİZ; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; GHE-4236-2022; CMF-4757-2022Publication Diagnostic dilemma of paraneoplastic arthritis: Case series(Wiley-blackwell, 2014-07-01) Kısacık, Bünyamin; Onat, Ahmet M.; Kaşifoğlu, Timuçin; Pehlivan, Yavuz; Pamuk, Ömer N.; Dönmez, Salim; Bilge, Sule Y.; Yilmaz, Sedat; Erdem, Hakan; Mercan, Ridvan; Özturk, Mehmet A.; Beş, Cemal; Soy, Mehmet; Erten, Sukran; Çobankara, Veli; Senel, Soner; Öner, Fatma A.; Direskeneli, Haner; Yılmaz, Sema; Yazıcı, Ayten; Emmungil, Hakan; Aksu, Kenan; Kul, Seval; Çetin, Gozde Y.; Sayarlıoğlu, Mehmet; DALKILIÇ, HÜSEYİN EDİZ; 0000-0002-6265-5227; 0000-0003-1537-2192; 0000-0003-1096-7306; 0000-0003-1710-7018; 0000-0003-0717-8365; 0000-0003-2598-5806; 0000-0002-4839-3777; 0000-0003-2167-4509; 0000-0001-5184-4404; JUV-4187-2023; JFJ-3399-2023; W-3342-2017; AAT-3636-2020; AAG-7687-2020; IZE-6133-2023; AAG-8227-2021; AAR-2072-2020; AAD-1796-2021; HLH-8218-2023; J-9960-2019; AAS-5508-2020; AAD-5233-2020Objectives: Paraneoplastic arthritis (PA) may mimic rheumatic diseases. While presenting the demographic and laboratory features of the patients diagnosed with PA, this study also aims to provide possible appropriate tools to differentiate the PA cases from early rheumatoid arthritis (ERA).Methods: Sixty-five patients with PA (male/female: 43/22) from 15 different rheumatology clinics and 50 consecutive patients with ERA (male/female: 13/37) fulfilling the 2010 American College of Rheumatology (ACR) criteria for the diagnosis if the RA from Gaziantep Rheumatology Early Arthritis Trial (GREAT) as controls who were diagnosed at least 12 months before, were enrolled into study.Results: Mean ages of the patients with PA and ERA were 50.2 +/- 15.3, and 42.7 +/- 12.3, respectively, and the mean ages of the patients with PA were significantly higher than the ERA. Unlike the ERA patients, in our case series PA was predominantly observed among males. Oligoarthritis was significantly higher in solid tumors in contrast to ERA (P = 0.001). Polyarthritis and symmetric arthritis were significantly higher in the ERA group in contrast to all malignancies (P = 0.001). Rheumatoid factor (RF) and anticyclic citrullinated peptide antibody (anti-CCP) positivity were significantly higher in the ERA group (each P = 0.001). Lactic dehydrogenase levels of hematologic malignancies were significantly higher than other groups (each, P = 0.001).Conclusions: ERA patients had more symmetric joint involvement than PA; laboratory markers could be also an alternative where there is high RF and anti-CCP positivity with antibody levels among the ERA patients. Finally, the demographic features can be used as differentiatingPublication Identification of susceptibility loci for takayasu arteritis through a large multi-ancestral genome-wide association study(Cell Press, 2021-01-07) Ortiz-Fernandez, Lourdes; Saruhan-Direskeneli, Guher; Alibaz-Oner, Fatma; Kaymaz-Tahra, Sema; Coit, Patrick; Kong, Xiufang; Kiprianos, Allan P.; Maughan, Robert T.; Aydin, Sibel Z.; Aksu, Kenan; Keser, Gokhan; Kamali, Sevil; Inanc, Murat; Springer, Jason; Akar, Servet; Onen, Fatos; Akkoc, Nurullah; Khalidi, Nader A.; Koening, Curry; Karadag, Omer; Kiraz, Sedat; Forbess, Lindsy; Langford, Carol A.; McAlear, Carol A.; Ozbalkan, Zeynep; Yavuz, Sule; Cetin, Gozde Yildirim; Alpay-Kanitez, Nilufer; Chung, Sharon; Ates, Askin; Karaaslan, Yasar; McKinnon-Maksimowicz, Kathleen; Monach, Paul A.; Ozer, Huseyin T. E.; Seyahi, Emire; Fresko, Izzet; Cefle, Ayse; Seo, Philip; Warrington, Kenneth J.; Ozturk, Mehmet A.; Ytterberg, Steven R.; Cobankara, Veli; Onat, Ahmet Mesut; Duzgun, Nursen; Bicakcigil, Muge; Yentur, Sibel P.; Lally, Lindsay; Manfredi, Angelo A.; Baldissera, Elena; Erken, Eren; Yazici, Ayten; Kisacik, Bunyamin; Kasifoglu, Timucin; Dalkilic, Ediz; Cuthbertson, David; Pagnoux, Christian; Sreih, Antoine; Reales, Guillermo; Wallace, Chris; Wren, Jonathan D.; Cunninghame-Graham, Deborah S.; Vyse, Timothy J.; Sun, Ying; Chen, Huiyong; Grayson, Peter C.; Tombetti, Enrico; Jiang, Lindi; Mason, Justin C.; Merkel, Peter A.; Direskeneli, Haner; Sawalha, Amr H.; 0000-0002-0247-4280; 0000-0003-0660-764X; 0000-0003-4153-903X; 0000-0001-7289-1816; 0000-0002-6376-5583; 0000-0002-3734-1242; 0000-0002-6341-2622; 0000-0002-3718-171X; 0000-0002-8270-2617; 0000-0003-1372-1555; 0000-0003-1185-5816; 0000-0003-4937-0515; 0000-0001-8764-4543; 0000-0003-4965-2918; 0000-0002-8914-9690; 0000-0001-7708-2487; 0000-0002-4530-7167; 0000-0002-7054-1203; 0000-0003-2167-4509; 0000-0002-3785-9834; 0000-0001-6287-9549; 0000-0002-7864-0185; 0000-0001-9993-3916; 0000-0001-9755-1703; 0000-0003-2776-3545; 0000-0003-1123-1464; 0000-0002-7122-9713; 0000-0001-7783-1660; 0000-0001-9284-7345; 0000-0003-2598-5806; GPP-1272-2022; CAG-1626-2022; ISU-1002-2023; D-2668-2012; AAA-6647-2020; AAT-3653-2020; HLH-8218-2023; AAT-3636-2020; KLZ-4006-2024; W-7332-2019; D-9870-2011; GOJ-7451-2022; C-4612-2015; KHW-8303-2024; AAD-5448-2019; AAA-8970-2021; P-4517-2015; L-1241-2015; HJI-6996-2023; JFJ-3399-2023; AAB-3576-2020; C-7018-2014; K-5378-2018Takayasu arteritis is a rare inflammatory disease of large arteries. We performed a genetic study in Takayasu arteritis comprising 6,670 individuals (1,226 affected individuals) from five different populations. We discovered HLA risk factors and four non-HLA susceptibility loci in VPS8, SVEP1, CFL2, and chr13q21 and reinforced IL12B, PTK2B, and chr21q22 as robust susceptibility loci shared across ancestries. Functional analysis proposed plausible underlying disease mechanisms and pinpointed ETS2 as a potential causal gene for chr21q22 association. We also identified >60 candidate loci with suggestive association (p < 5 x 10(-s)) and devised a genetic risk score for Takayasu arteritis. Takayasu arteritis was compared to hundreds of other traits, revealing the closest genetic relatedness to inflammatory bowel disease. Epigenetic patterns within risk loci suggest roles for monocytes and B cells in Takayasu arteritis. This work enhances understanding of the genetic basis and pathophysiology of Takayasu arteritis and provides clues for potential new therapeutic targets.Publication Identification of susceptibility loci in IL6, RPS9/LILRB3, and an intergenic locus on chromosome 21q22 in Takayasu Arteritis in a genome-wide association study(Wiley, 2015-05-01) Renauer, Paul A.; Saruhan-Direskeneli, Guher; Coit, Patrick; Adler, Adam; Aksu, Kenan; Keser, Gökhan; Alibaz-Öner, Fatma; Aydın, Sibel Z.; Kamali, Sevil; İnanç, Murat; Carette, Simon; Cuthbertson, David; Hoffman, Gary S.; Akar, Servet; Önen, Fatoş; Akkoç, Nurullah; Khalidi, Nader A.; Koening, Curry; Karadağ, Ömer; Kiraz, Sedat; Langford, Carol A.; Maksimowicz-McKinnon, Kathleen; McAlear, Carol A.; Özbalkan, Zeynep; Ateş, Aşkın; Karaaslan, Yaşar; Düzgün, Nursen; Monach, Paul A.; Özer, Hüseyin T. E.; Erken, Eren; Öztürk, Mehmet A.; Yazıcı, Ayten; Cefle, Ayşe; Onat, Ahmet Mesut; Kısacık, Bünyamin; Pagnoux, Christian; Kaşifoğlu, Timuçin; Seyahi, Emire; Fresko, İzzet; Seo, Philip; Sreih, Antoine G.; Warrington, Kenneth J.; Ytterberg, Steven R.; Cobankara, Veli; Cunninghame-Graham, Deborah S.; Vyse, Timothy J.; Pamuk, Ömer N.; Tunç, S. Ercan; Dalkılıç, Ediz; Bıçakçıgil, Müge; Yentur, Sibel P.; Wren, Jonathan D.; Merkel, Peter A.; Direskeneli, Haner; Sawalha, Amr H.; DALKILIÇ, HÜSEYİN EDİZ; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; CMF-4757-2022Objective. Takayasu arteritis is a rare large vessel vasculitis with incompletely understood etiology. This study was undertaken to perform the first unbiased genome-wide association analysis of Takayasu arteritis.Methods. Two independent cohorts of patients with Takayasu arteritis from Turkey and North America were included in our study. The Turkish cohort consisted of 559 patients and 489 controls, and the North American cohort consisted of 134 patients and 1,047 controls of European ancestry. Genotyping was performed using the Omni1-Quad and Omni2.5 genotyping arrays. Genotyping data were subjected to rigorous quality control measures and subsequently analyzed to discover genetic susceptibility loci for Takayasu arteritis.Results. We identified genetic susceptibility loci for Takayasu arteritis with a genome-wide level of significance in IL6 (rs2069837) (odds ratio [OR] 2.07, P = 6.70 x 10(-9)), RPS9/LILRB3 (rs11666543) (OR 1.65, P = 2.34 x 10(-8)), and an intergenic locus on chromosome 21q22 (rs2836878) (OR 1.79, P = 3.62 x 10(-10)). The genetic susceptibility locus in RPS9/LILRB3 lies within the leukocyte receptor complex gene cluster on chromosome 19q13.4, and the disease risk variant in this locus correlates with reduced expression of multiple genes including the inhibitory leukocyte immunoglobulin-like receptor gene LILRB3 (P = 2.29 x 10(-8)). In addition, we identified candidate susceptibility genes with suggestive levels of association (P < 1 x 10(-5)) with Takayasu arteritis, including PCSK5, LILRA3, PPM1G/NRBP1, and PTK2B.Conclusion. Our findings indicate novel genetic susceptibility loci for Takayasu arteritis and uncover potentially important aspects of the pathophysiology of this form of vasculitis.Item The IL-33 gene is related to increased susceptibility to systemic sclerosis(Springer Heidelberg, 2015-12-23) Koca, Süleyman Serdar; Kara, Murat; Alibaz-Öner, Fatma; Öztuzcu, Serdar; Yılmaz, Neslihan; Çetin, Gözde Yıldırım; Kısacık, Bünyamin; Özgen, Metin; Pamuk, Ömer Nuri; Direskeneli, Haner; Sayarlıoğlu, Mehmet; Onat, Ahmet Mesut; Pehlivan, Yavuz; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; AAG-8227-2021; 13205593600Systemic sclerosis (SSc) is a chronic inflammatory disease characterized by widespread fibrosis of the skin and several visceral organs. The pro-fibrotic potential of interleukin (IL)-33 has been demonstrated by in both in vitro and in vivo settings; moreover, increased level of IL-33 has also been reported in patients with SSc. Therefore, the aim of the present study was to detect the potential association of IL-33 gene polymorphisms on the susceptibility of SSc. A total of 300 SSc patients and 280 healthy controls (HC) were enrolled in this multicentric preliminary candidate gene study. DNA samples were harvested using an appropriate commercial DNA isolation kit. Four single nucleotide polymorphisms (SNPs) of IL-33 gene (rs7044343, rs1157505, rs11792633 and rs1929992) were genotyped using the appropriate commercial primer/probe sets on real-time PCR. There was no significant difference in terms of the allelic distributions and minor allele frequencies of evaluated four IL-33 polymorphisms between the SSc and HC groups (P > 0.05 for all). Moreover, the genotypic distributions of rs1157505, rs11792633 and rs1929992 polymorphisms were not significantly different (P > 0.05 for all). However, CC genotype of rs7044343 SNP was significantly higher in the SSc group compared to the HC group (P = 0.013, OR 1.75, 95 % CI 1.12-2.72). This preliminary candidate gene study demonstrates that rs7044343 polymorphism of IL-33 gene is associated with the susceptibility to the SSc in Turkish population. It may be suggested that IL-33 gene may be a candidate gene to research in SSc.Item Incidence of cyclophosphamide-induced urotoxicity and protective effect of mesna in rheumatic diseases(J Rheumatol Publication, 2015-09) Yılmaz, Neslihan; Emmungil, Hakan; Gücenmez, Sercan; Özen, Gülşen; Yıldız, Fatih; Balkarlı, Ayşe; Kimyon, Gezmiş; Doğan, İsmail; Pamuk, Ömer Nuri; Yaşar, Şule; Çetin, Gözde Yıldırım; Yazıcı, Ayten; Eşmen, Serpil Ergülü; Cağatay, Yonca; Yılmaz, Sema; Cefle, Ayşe; Sayarlıoğlu, Mehmet; Kaşifoğlu, Timuçin; Karadağ, Ömer; KIsacık, Bünyamin; Çobankara, Veli; Erken, Eren; Direskeneli, Haner; Aksu, Kenan; Yavuz, Şule; Coşkun, Belkıs Nihan; Pehlivan, Yavuz; Dalkılıç, Ediz; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; 0000-0003-0298-4157; AAG-8227-2021; AAG-7155-2021; 55646165400; 57220381538; 6506739457Objective. To assess bladder toxicity of cyclophosphamide (CYC) and uroprotective effect of mesna in rheumatic diseases. Methods. Data of 1018 patients (725 women/293 men) treated with CYC were evaluated in this retrospective study. All of the following information was obtained: the cumulative CYC dose, route of CYC administration, duration of therapy, concomitant mesna usage, and hemorrhagic cystitis. Cox proportional hazard model was used for statistics. Results. We identified 17 patients (1.67%) with hemorrhagic cystitis and 2 patients (0.19%) with bladder cancer in 4224 patient-years. The median time for diagnosis to hemorrhagic cystitis was 10 months (4-48) and bladder cancer was 8 years (6-10.9). There were 583 patients (57.2%) who received mesna with intravenous CYC therapy. We observed similar incidence rate for hemorrhagic cystitis in both patient groups concomitantly treated with or without mesna [9/583 (1.5%) vs 8/425 (1.8%) respectively, p = 0.08]. Cumulative CYC dose (HR for 10-g increments 1.24, p < 0.001) was associated with hemorrhagic cystitis. Conclusion. Cumulative dose was the only risk factor for hemorrhagic cystitis in patients treated with CYC. No proof was obtained for the uroprotective effect of mesna in our cohort.Publication Interim analysis of baseline characteristics and preferences of administration route of rheumatoid arthritis patients who are bio-naive or switched between advanced ra treatments; a multicenter, prospective, observational study(Wiley, 2018-09-01) Direskeneli, Haner; Karadağ, Ömer; Ateş, Aşkın; Tufan, Abdurrahman; İnanç, Nevsun; Koca, Süleyman Serdar; Çetin, Gözde Yıldırım; Akar, Servet; Çınar, Muhammet; Yılmaz, Sedat; Yılmaz, Neslihan; Dalkılıç, Ediz; Beş, Cemal; Özbalkan, Zeynep; Yılmazer, Bariş; Şahin, Ali; Ersözlü, Emine Duygu; Tezcan, Mehmet Engin; Şen, Nesrin; Keser, Gökhan; Tansoker, İlkan; Hacıbedel, Fatma Başak; Helvacıoğlu, Kerem; Günay, Levent Mert; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi; CMF-4757-2022Item Investigation of poor prognostic factors among rheumatoid arthritis patients in Turkbio registry(Wiley, 2017-10) İnanç, Nevsun; Ertürk, Zeynep; Özen, Gülşen; Koca, Süleyman Serdar; Can, Gerçek; Karataş, Ahmet; Yazıcı, Ayten; Cefle, Ayşe; Akar, Servet; Şenel, Soner; Öz, Burak; Akkoç, Nurullah; Direskeneli, Haner; Önen, Fatoş; Dalkılıç, Ediz; Pehlivan, Yavuz; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Romatoloji Anabilim Dalı.; AAG-8227-2021Item Investigation of poor prognostic factors among rheumatoid arthritis patients in Turkbio registry(BMJ Publishing Group, 2018-06) İnanç, Nevsun; Ertürk, Zeynep; Özen, Gülşen; Koca, Süleyman Serdar; Can, Gerçek; Karataş, Ahmet; Yazıcı, Ayten; Cefle, Ayşe; Akar, Servet; Şenel, Soner; Öz, Burak; Akkoç, Nurullah; Direskeneli, Haner; Dalkılıç, Ediz; Pehlivan, Yavuz; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Bilim Dalı.; JHC-5173-2023; FQP-0451-2022Item Investigation of the association between Rho/Rho-kinase gene polymorphisms and systemic sclerosis(Springer, 2015-11-17) Yolbaş, Servet; Çetin, Gözde Yıldırım; Alibaz, Fatma Öner; Çağatay, Yonca; Yılmaz, Neslihan; Öztuzcu, Serdar; Dönmez, Salim; Özgen, Metin; Koca, Süleyman Serdar; Pamuk, Ömer Nuri; Sayarlıoğlu, Mehmet; Kısacık, Bünyamin; Direskeneli, Haner; Demiryürek, Abdullah Tuncay; Onat, Ahmet Mesut; Pehlivan, Yavuz; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Romatoloji Bilim Dalı.; AAG-8227-2021; 13205593600Systemic sclerosis (SSc) is a disease characterized by inflammation, vascular abnormalities and fibrosis. The role of Rho/Rho-kinase pathway was demonstrated in the pathogenesis of fibrosis, inflammation and vascular abnormalities. This study was aimed to investigate the relation between SSc and Rho/Rho-kinase gene polymorphisms. The study included 339 patients with SSc and 302 healthy subjects who were apparently healthy and at similar age and gender. Genotype distributions and allele frequencies were detected by using Chi-square test or Fisher's exact Chi-square test between groups, and the haplotype analysis was applied using online program (SHEsis). Significant association was found in a polymorphism in the ROCK1 gene (rs35996865), a polymorphism in ROCK2 gene (rs10178332), a polymorphism in RhoA gene (rs2177268) and two polymorphisms in RhoC gene (rs11102522 and rs11538960) with SSc disease (p < 0.0022). In this study, association between SSc disease and Rho/Rho-kinase gene polymorphisms was investigated for the first time; significant associations between ROCK1, ROCK2, RhoA and RhoC gene polymorphisms and SSc disease were demonstrated. The results strongly suggest that this SNP may be an important risk factor for development of SSc. However, further validation of these findings in an independent cohort is necessary.Publication Predictors for the risk and severity of post-thrombotic syndrome in vascular Behcet's disease(Elsevier, 2021-02-04) Aksoy, Aysun; Çolak, Seda; Yağız, Burcu; Coşkun, Belkıs Nihan; Omma, Ahmet; Yıldız, Yasin; Sarı, Alper; Ataş, Nuh; Ilgın, Can; Karadağ, Ömer; Erden, Abdulsamet; Dalkılıç, Ediz; Bolca, Naile; Ergelen, Rabia; Onur, Mehmet Ruhi; Direskeneli, Haner; Alibaz-Öner, Fatma; YAĞIZ, BURCU; COŞKUN, BELKIS NİHAN; BOLCA TOPAL, NAİLE; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Romatoloji Bilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Radyoloji Anabilim Dalı.; 0000-0003-0298-4157; JQW-5031-2023; AAG-7155-2021; CMF-4757-2022 ; EKW-9201-2022Objective: Deep vein thrombosis (DVT) of the lower extremities is the most common form of vascular involvement in Behcet disease (BD), frequently leading to post-thrombotic syndrome (PTS) as a disabling complication. We have described the clinical characteristics and predictors of PTS presence among patients with BD and lower extremity DVT. We also used venous Doppler ultrasound (US) examinations in our assessment. Methods: Patients with BD (n = 205; 166 men, 39 women; age 39 6 9.5 years) and a history of DVT were investigated. The Villalta scale was used to assess the presence and severity of PTS. Doppler US examinations were performed within 1 week of the clinical evaluation. The total number of vessels with reflux, thrombi, recanalization, and collateral vessels were calculated. Results: Of the 205 patients with BD, 62% had had PTS and 18% had had severe PTS. Patients with PTS had had greater reflux (P = .054) and thrombosis (P = .02) scores compared with patients without PTS. Treatment with anticoagulation (AC), immunosuppressive (IS) therapy, or AC combined with IS drugs did not affect the occurrence of PTS. However, patients treated with IS therapy, with or without AC drugs, had a decreased incidence of severe PTS compared with the AC-only group (P = .017). Patients treated with AC plus IS agents also had increased collateral scores compared with patients treated with only IS drugs. Interferon-a use seemed to provide better recanalization scores compared with azathioprine only (1.0 [range, 0-14] vs 2.5 [range, 0-10]; P = .010). Conclusions: Patients with BD and DVT have a high risk of developing severe PTS. IS treatment decreases the development of severe PTS. AC therapy might influence the course of PTS by increasing the collateral scores, and the use of interferon-a also increased recanalization scores. Routine assessment with Doppler US examinations could be helpful in the prediction of severe PTS.Item Similiar efficacy of tofacinitib on disease activity in rheumatoid arthritis patients with and without previous biologicals; Results from the turkbio registry(Wiley, 2018-09) Zengin, Berrin; İnanç, Nevsun; Akar, Servet; Can, Gerçek; Tufan, Abdulrahman; Şenel, Soner; Koca, Süleyman Serdar; Yarkan, Handan; Ertürk, Zeynep; Göker, Berna; Direskeneli, Haner; Birlik, Merih; Akkoç, Nurullah; Önem, Fatoş; Dalkılıç, Ediz; Pehlivan, Yavuz; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Bilim Dalı.; AAG-8227-2021Item Tuberculosis reactivation risk in patients treated with tumor necrosis factor alpha inhibitors: a turkish experience with higher mortality and different background diseases.(Wiley, 2014-10) Kısacık, Bünyamin; Pamuk, Ömer; Onat, Ahmet Mesut; Erer, Burak; Hatemi, Gülen; Özgüler, Yeşim; Kılıç, Levent; Ertenli, İhsan; Can, Meryem; Direskeneli, Haner; Keser, Gökhan; Öksel, Fahrettin; Yılmaz, Sedat; Pay, Salih; Balkarlı, Ayşe; Çobankara, Veli; Çetin, Gözde Yıldırım; Sayarlıoğlu, Mehmet; Cefle, Ayşe; Yazıcı, Ayten; Avcı, Ali Berkant; Terzioğlu, Ender; Özbek, Süleyman; Akar, Servet; Gül, Ahmet; Pehlivan, Yavuz; Dalkılıç, Ediz; Uludağ Üniversitesi/Tıp Fakültesi.; AAG-8227-2021